ReviewJapanese journal of radiology2023
Imaging of pituitary tumors: an update with the 5th WHO Classifications-part 2. Neoplasms other than PitNET and tumor-mimicking lesions.
Review in Japanese journal of radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Quality requirements for MRI simulation in cranial stereotactic radiotherapy: a guideline from the German Taskforce "Imaging in Stereotactic Radiotherapy".Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Guideline
- A third ventricular floor-associated TTF-1-positive posterior pituitary tumor: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- MRI mimics of primary empty sella: a retrospective educational case series highlighting clinical and uncommon magnetic resonance imaging presentations.Acta neurologica Belgica · 2026Article
- Posterior Pituitary and Hypothalamic Neuronal Tumors in the 5th WHO Classification: Molecular Insights, Diagnostic Markers, and Clinical Management.International journal of molecular sciences · 2026Review
- Systematic proteomic analysis of neuroimaging metrics identifies therapeutic targets for pituitary neuroendocrine.NPJ systems biology and applications · 2026Article
- Illuminating radiogenomic signatures in pediatric-type diffuse gliomas: insights into molecular, clinical, and imaging correlations. Part I: high-grade group.La Radiologia medica · 2025Review
- Combined Use of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in the Differential Diagnosis of Sellar Tumors: A Single-Centre Experience.Journal of clinical medicine · 2025Article
- Illuminating radiogenomic signatures in pediatric-type diffuse gliomas: insights into molecular, clinical, and imaging correlations. Part II: low-grade group.La Radiologia medica · 2025Review
- Advances in multimodal imaging for adrenal gland disorders: integrating CT, MRI, and nuclear medicine.Japanese journal of radiology · 2025Review
- Endoscopic endonasal surgery for suprasellar ectopic pituitary neuroendocrine tumors featuring apoplexy and a preoperative differential diagnosis: illustrative cases.Journal of neurosurgery. Case lessons · 2025Article
- Role of diffusion-weighted imaging in the diagnosis of pituitary region tumors.Neuroradiology · 2025Article
- Comparison of clinical and radiological characteristics of inflammatory and non-inflammatory Rathke cleft cysts.Japanese journal of radiology · 2025Article
- A Real-World Longitudinal Study in Non-Functioning Pituitary Incidentalomas: A PRECES Micro-Adenomas Sub-Analysis.Diseases (Basel, Switzerland) · 2024Article
- Review
- Multidisciplinary Team Care in Pituitary Tumours.Cancers · 2024Review
- Neuroimaging of hypophysitis: etiologies and imaging mimics.Japanese journal of radiology · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many types of tumors can develop in the pituitary gland. In the recently revised 5th editions of the World Health Organization (WHO) classifications (2021 WHO Classification of Central Nervous System Tumors and the 2022 WHO Classification of Endocrine and Neuroendocrine Tumors), various changes have been made to the tumors other than pituitary neuroendocrine tumor (PitNET)/pituitary adenoma, as well as PitNET. Adamantinomatous craniopharyngioma and papillary craniopharyngioma are now considered separate tumors in the 5th edition of the WHO classification. Tumors positive for thyroid transcription factor 1, a marker of posterior pituitary cells, are now grouped together in the pituicyte tumor family in the 5th edition of the WHO classification of Endocrine and Neuroendocrine Tumors. Poorly differentiated chordoma is newly listed in the 5th edition of the WHO Classification of Endocrine and Neuroendocrine Tumors. In this paper, we present the latest WHO classification of pituitary tumors (adamantinomatous craniopharyngioma, papillary craniopharyngioma, pituitary blastoma, pituicyte tumor family, tumors of pituitary origin other than those of the pituicyte tumor family, germinoma, meningioma, chordoma, metastatic tumors, lymphoma, and pituitary incidentaloma), review diseases requiring differentiation from tumors (pituitary abscess, hypophysitis, pituitary hyperplasia, Rathke's cleft cyst, arachnoid cyst, and aneurysm), and discuss diagnoses based on imaging findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.